TCGA-22-4594-01A-01R-1201-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.510
- OXIDATIVE_PHOSPHORYLATION+0.480
- DNA_REPAIR+0.340
- MYC_TARGETS_V1+0.340
- ALLOGRAFT_REJECTION+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.290
- FATTY_ACID_METABOLISM+0.260
- PROTEIN_SECRETION+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.240
- MTORC1_SIGNALING+0.230
Top 10 suppressed
- APICAL_SURFACE-0.430
- MITOTIC_SPINDLE-0.390
- HEDGEHOG_SIGNALING-0.360
- ANGIOGENESIS-0.350
- APICAL_JUNCTION-0.340
- UV_RESPONSE_DN-0.340
- WNT_BETA_CATENIN_SIGNALING-0.330
- TGF_BETA_SIGNALING-0.280
- INTERFERON_ALPHA_RESPONSE-0.250
- MYOGENESIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.849 |
| 2 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.812 |
| 3 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.807 |
| 4 | TCGA-05-5428-01A-01R-1628-07 | — | cohortA1 | 0.788 |
| 5 | 57901dc3-9b2f-4271-8dd9-8fc0121d6971 | — | — | 0.786 |
| 6 | TCGA-37-4135-01A-01R-1100-07 | — | cohortA1 | 0.783 |
| 7 | C3L-01862 | — | cohortA4 | 0.781 |
| 8 | SRR27320676 | — | — | 0.776 |
| 9 | TCGA-38-4631-01A-01R-1755-07 | — | cohortA4 | 0.775 |
| 10 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |